Latest & greatest articles for nifedipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nifedipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nifedipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nifedipine

21. Nifedipine in the management of preterm labor: a systematic review and metaanalysis Full Text available with Trip Pro

Nifedipine in the management of preterm labor: a systematic review and metaanalysis To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor.A systematic review and metaanalysis of randomized controlled trials.Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing (...) enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β₂-adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β₂-adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared

2011 EvidenceUpdates

22. Nifedipine as a uterine relaxant for external cephalic version: a randomized controlled trial Full Text available with Trip Pro

Nifedipine as a uterine relaxant for external cephalic version: a randomized controlled trial To estimate the effectiveness of nifedipine as a uterine relaxant during external cephalic version to correct breech presentation.In this randomized, double-blind, placebo-controlled trial, women with a singleton fetus in breech presentation and a gestational age of 36 weeks or more were eligible for enrollment. Participating women received two doses of either nifedipine 10 mg or placebo, 30 and 15 (...) no significant difference in external cephalic version success rates between treatment (42%) and control group (37%) (relative risk 1.1, 95%; 95% confidence interval 0.85-1.5). The cesarean delivery rate was 51% in the treatment group and 46% in the control group (relative risk 1.1, 95% confidence interval 0.88-1.4).Nifedipine did not significantly improve the success of external cephalic version. Future use of nifedipine to improve the outcome of external cephalic version should be limited to large clinical

2008 EvidenceUpdates Controlled trial quality: predicted high

23. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension. The Nifedipine and Candesartan Combination (NICE-Combi) study

Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension. The Nifedipine and Candesartan Combination (NICE-Combi) study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

24. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. (Abstract)

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Calcium antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controversial. We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris.We randomly assigned 3825 patients with treated stable symptomatic coronary (...) disease to double-blind addition of nifedipine GITS (gastrointestinal therapeutic system) 60 mg once daily and 3840 to placebo. The primary endpoint was the combination of death, acute myocardial infarction, refractory angina, new overt heart failure, debilitating stroke, and peripheral revascularisation. Mean follow-up was 4.9 years (SD 1.1). Analysis was by intention to treat.310 patients allocated nifedipine died (1.64 per 100 patient-years) compared with 291 people allocated placebo (1.53 per 100

2004 Lancet Controlled trial quality: predicted high

25. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). (Abstract)

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). The efficacy of antihypertensive drugs newer than diuretics and beta-blockers has not been established. We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity (...) in high-risk patients with hypertension.We did a prospective, randomised, double-blind trial in Europe and Israel in 6321 patients aged 55-80 years with hypertension (blood pressure > or = 150/95 mm Hg, or > or = 160 mm Hg systolic). Patients had at least one additional cardiovascular risk factor. We randomly assigned patients nifedipine 30 mg in a long-acting gastrointestinal-transport-system (GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mg [corrected] plus amiloride 2.5 mg; n

2000 Lancet Controlled trial quality: predicted high

26. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. (Abstract)

Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has been

2000 Cochrane

27. Safety of nifedipine in angina pectoris: a meta-analysis

Safety of nifedipine in angina pectoris: a meta-analysis Safety of nifedipine in angina pectoris: a meta-analysis Safety of nifedipine in angina pectoris: a meta-analysis Stason W B, Schmid C H, Niedzwiecki D, Whiting G W, Caubet J F, Cory D, Luo D, Ross S D, Chalmers T C Authors' objectives To compare cardiovascular event rates in patients with stable angina receiving nifedipine as monotherapy or combination therapy and in active drug controls. Searching MEDLARS (1966 to August 1995 (...) ) was searched using the exploded MESH term "myocardial ischemia" and "nifedipine" as a textword. Studies published in English, French, Italian, German and Spanish languages were included. CD-ROM Current Contents and bibliographies of retrieved articles were also searched. Study selection Study designs of evaluations included in the review Published randomised controlled trials (RCTs) that enrolled a minimum of 10 patients. Specific interventions included in the review Any nifedipine formulation, either

1999 DARE.

28. Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis

Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Oei S G, Mol B W, de Kleine M J, Brolmann H A Authors' objectives To assess the effectiveness of nifedipine and ritodrine in the suppression of pre-term labour. Searching MEDLINE was searched from January 1966 to November 1998, and EMBASE from January 1980 (...) to November 1998, using the following keywords: 'nifedipine', 'ritodrine' and 'randomised'. Cross-references of selected studies were checked. A formal assessment of publication bias was not possible due to small sample sizes. Study selection Study designs of evaluations included in the review Randomised clinical trials (RCTs) were eligible. Specific interventions included in the review Direct comparisons of ritodrine and nifedipine were eligible. Ritodrine doses (where stated) ranged from an infusion

1999 DARE.

29. Clinical and economic outcomes of a nifedipine-to-felodipine switch program

Clinical and economic outcomes of a nifedipine-to-felodipine switch program Clinical and economic outcomes of a nifedipine-to-felodipine switch program Clinical and economic outcomes of a nifedipine-to-felodipine switch program Dearing C J, Briscoe T A, Morgan S M, Block L C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Second generation dihydropyridine calcium channel blockers for the treatment of hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with hypertension switching from treatment with nifedipine to treatment with felodipine. Setting Outpatient clinic. The economic analysis was conducted in Atlanta, Georgia, USA. Dates to which data relate

1998 NHS Economic Evaluation Database.

30. Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy]

Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Lievre M, Cucherat M Authors' objectives The authors state that their objective is to assess criticisms (...) levied at a previously published meta-analysis of nifedipine for coronary heart disease (Furberg et al 1995 - see Other Publications of Related Interest). However, they also appear to have attempted to extend the review, in order to provide additional data. Searching Data were used from the review by Furberg et al 1995 (see Other Publications of Related Interest). Other sources included MEDLINE (search terms and years searched not provided) and handsearching of English, French, Italian, Spanish

1997 DARE.

31. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension

Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Malik A S, Warshafsky S, Lehrman S Authors' objectives Assess the magnitude and consistency of the effect of nifedipine on reducing pulmonary artery pressure (PAP) in patients with pulmonary hypertensive disorders. Searching MEDLINE was searched from 1966 (...) to 1995 using the keywords field for the combination 'nifedipine' and 'pulmonary hypertension'. Bibliographies of retrieved articles were also reviewed. Study selection Study designs of evaluations included in the review Case series were included. Specific interventions included in the review Nifedipine (30 to more than 200 mg/day). Participants included in the review Patients with the following illnesses were included in the analysis: pulmonary hypertension secondary to chronic obstructive pulmonary

1997 DARE.

32. Safety of nifedipine in patients with hypertension: a meta-analysis

Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Stason W B, Schmid C H, Niedzwiecki D, Whiting G W, Caubet J-F, Luo D, Ross S D, Chalmers T C Authors' objectives To compare cardiovascular event rates in patients with mild or moderate hypertension who received nifedipine with active drug controls. Searching MEDLARS was searched from 1966 (...) to August 1995 using the MeSH 'hypertension' and 'nifedipine' as a textword. Studies published in English, French, Italian, German or Spanish were included. Current Contents (CD-ROM), and the bibliographies of retrieved articles were also searched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included if they had a minimum of 10 patients, were published in a peer-reviewed journal or supplement to such a journal, and reported adverse events

1997 DARE.

33. Nifedipine: dose-related increase in mortality in patients with coronary heart disease

Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Furberg C D, Psaty B M, Meyer J V Authors' objectives To assess the effect of nifedipine dose on mortality and to review the potential mechanisms of such an effect. Searching The authors do not provide details of the sources searched (...) or the strategies used. Study selection Study designs of evaluations included in the review All published randomised controlled trials (RCTs) of nifedipine in the secondary prevention of CHD for which mortality data were available, were included. Specific interventions included in the review Nifedipine at doses of 30, 40, 50, 60, 80 and 100 mg/day, to a maximum of 120 mg. Participants included in the review Patients with coronary heart disease (CHD). Of the 16 studies included, 12 included patients

1995 DARE.

34. Use of nifedipine in the hypertensive diseases of pregnancy

Use of nifedipine in the hypertensive diseases of pregnancy Use of nifedipine in the hypertensive diseases of pregnancy Use of nifedipine in the hypertensive diseases of pregnancy Levin A C, Doering P L, Hatton R C Authors' objectives To review available data about the use of nifedipine to treat hypertension in pregnancy. Searching MEDLINE, Excerpta Medica and BIOSIS Previews were searched from 1984 onwards for studies published in the English language, using the headings 'nifedipine (...) ', 'hypertension in pregnancy', 'uteroplacental blood flow', 'maternal/fetal hemodynamics', 'pre-eclampsia' and 'pregnancy outcome'. Study selection Study designs of evaluations included in the review The authors do not provide any details of the designs of the included studies. Specific interventions included in the review Acute administration of nifedipine, either alone or in conjunction with other blood-pressure medications including hydralazine, methyldopa, labetalol, atenolol, or methyldopa plus atenolol

1994 DARE.

35. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. (Abstract)

Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. Vasodilator therapy with nifedipine reduces left ventricular volume and mass and increases the ejection fraction in asymptomatic patients with severe aortic regurgitation.To assess whether vasodilator therapy reduces or delays the need for valve replacement, we randomly assigned 143 asymptomatic patients with isolated, severe aortic regurgitation and normal left ventricular systolic (...) function to receive either nifedipine (20 mg twice daily, 69 patients) or digoxin (0.25 mg daily, 74 patients).By actuarial analysis, we determined that after six years a mean (+/- SD) of 34 +/- 6 percent of the patients in the digoxin group had undergone valve replacement, as compared with only 15 +/- 3 percent of those in the nifedipine group (P < 0.001). In the digoxin group, valve replacement (in a total of 20 patients) was performed because of left ventricular dysfunction (ejection fraction < 50

1994 NEJM Controlled trial quality: uncertain

36. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Full Text available with Trip Pro

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. To compare the efficacy, safety, and tolerance of enalapril and nifedipine in hypertensive patients with non-insulin dependent diabetes.One year double blind follow up of patients randomly allocated to either enalapril or nifedipine with matching placebos for the alternative drug.Metabolic Investigation Unit, Hong Kong.102 patients were randomised: 52 to nifedipine (...) and 50 to enalapril. At baseline 44 patients had normoalbuminuria, 36 microalbuminuria, and 22 macroalbuminuria.Blood pressure, albuminuria, and parameters of renal function and glycaemic control.In patients who completed one year's treatment the median dose required by the nifedipine group (n = 49) was 60 mg/day; seven (14%) required additional diuretics. Of 41 patients given enalapril, 37 required the maximum dose (40 mg/day) and 27 (76%) required diuretics. At one year mean arterial blood

1992 BMJ Controlled trial quality: uncertain

37. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. Full Text available with Trip Pro

Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. To compare the efficacy of angiotensin converting enzyme inhibition with calcium antagonism in diabetic patients with microalbuminuria.Randomised study of diabetic patients with microalbuminuria treated with perindopril or nifedipine for 12 months and monitored for one or three months after stopping treatment depending on whether (...) they were hypertensive or normotensive. Patients were randomised separately according to whether they were hypertensive or normotensive.Diabetic clinics in three university teaching hospitals.50 diabetic patients with persistent microalbuminuria. In all, 43 completed the study: 30 were normotensive and 13 hypertensive; 19 had type I diabetes and 24 had type II diabetes.For 12 months 20 patients were given perindopril 2-8 mg daily and 23 were given nifedipine 20-80 mg daily.Albumin excretion rate, blood

1991 BMJ Controlled trial quality: uncertain

38. Interaction of citrus juices with felodipine and nifedipine. (Abstract)

Interaction of citrus juices with felodipine and nifedipine. Six men with borderline hypertension took felodipine 5 mg with water, grapefruit juice, or orange juice. The mean felodipine bioavailability with grapefruit juice was 284 (range 164-469)% of that with water. The dehydrofelodipine/felodipine AUC ratio was lower, diastolic blood pressure lower, and heart rate higher with grapefruit juice than with water. Vasodilatation-related side-effects were more frequent. Orange juice had (...) no such effects. Six healthy men took nifedipine 10 mg with water or grapefruit juice; the bioavailability with grapefruit juice was 134 (108-169)% of that with water.

1991 Lancet Controlled trial quality: uncertain

39. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. (Abstract)

Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Many patients with angina pectoris whose symptoms are not completely controlled by beta-blockers are treated with several types of drugs, but it is not clear whether addition of a calcium-channel antagonist and/or a nitrate confers any advantage over beta-blockade alone. 18 patients receiving atenolol for stable angina pectoris completed a double-blind, randomised, crossover trial of atenolol (...) treatment plus placebo, isosorbide mononitrate, nifedipine, and mononitrate and nifedipine (triple therapy). The patients were assessed subjectively and by treadmill exercise testing and 24 h ambulatory electrocardiographic recordings at the end of each 4-week treatment period. There were no significant differences among the treatment periods in angina attack rates, glyceryl trinitrate consumption, exercise duration to onset of angina or 1 mm ST depression, or duration of symptomless ischaemia. Total

1991 Lancet Controlled trial quality: predicted high

40. Prevention of high-altitude pulmonary edema by nifedipine. (Abstract)

Prevention of high-altitude pulmonary edema by nifedipine. Exaggerated pulmonary-artery pressure due to hypoxic vasoconstriction is considered an important pathogenetic factor in high-altitude pulmonary edema. We previously found that nifedipine lowered pulmonary-artery pressure and improved exercise performance, gas exchange, and the radiographic manifestations of disease in patients with high-altitude pulmonary edema. We therefore hypothesized that the prophylactic administration (...) of nifedipine would prevent its recurrence.Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude. Both the subjects and the investigators were blinded to the assigned treatment

1991 NEJM Controlled trial quality: uncertain